Why Is Genetic Testing Used to Diagnose 46,XY DSD?
At a Glance
Genetic testing helps diagnose 46,XY DSD when hormone results overlap or change with age. Finding the genetic cause can clarify the condition and guide discussions about hormone therapy, gonad monitoring, tumor risk, and screening for other organs; a negative test does not rule out DSD.
In this answer
4 sections
A 46,XY difference of sex development (DSD) refers to conditions where a person has a 46,XY karyotype (the typical male chromosome pattern) but their reproductive anatomy (such as gonads or genitals) develops differently.
While blood tests are helpful for seeing how your hormones are working right now, they cannot always tell the whole story. Genetic testing—using technologies like Next-Generation Sequencing (NGS) for targeted gene panels or Whole Exome Sequencing (WES)—has become a crucial partner in diagnosing 46,XY DSD [1][2]. Hormone panels can sometimes be misleading because different conditions often look identical on a blood test [3][4]. While genetic testing doesn’t remove all uncertainty, identifying a specific genetic cause can narrow down the diagnosis, helping you and your multidisciplinary care team make more informed decisions about long-term health needs, cancer risks, and hormone therapies [5][6].
Why Hormone Tests Aren’t Always Enough
Hormone tests measure levels of androgens (hormones like testosterone that drive typical male development), estrogen, and other chemicals to see how the reproductive system is functioning [7]. However, relying solely on biochemical panels has limitations:
- Overlapping results: Several different DSDs can produce similar hormone profiles. For instance, the hormone levels in Partial Androgen Insensitivity Syndrome (PAIS) can look very similar to those in 5α-reductase deficiency (SRD5A2) or 17β-hydroxysteroid dehydrogenase 3 (HSD17B3) deficiency [8][4].
- Age-dependent accuracy: Hormone levels naturally fluctuate depending on age. A test that is informative during infancy might not be helpful during childhood before puberty begins [9][10].
- Complex ratios: Doctors sometimes use the ratio of testosterone to dihydrotestosterone (DHT) to suspect 5α-reductase deficiency. However, this ratio can be affected by age and other factors, and can be elevated in conditions like androgen insensitivity [3]. Molecular testing helps clarify these complex hormone pictures.
The Power (and Limits) of Genetic Testing
Genetic testing looks for a pathogenic variant (a DNA change known to cause a medical condition). NGS is a technology used to read DNA, often used to check a specific “panel” of known DSD-related genes [11]. WES examines the protein-coding regions of your genes [12]. While WES is broad, it does not look at every single piece of DNA and can miss certain structural changes or hidden variants.
If a specific variant is found, it can help guide care:
- Understanding hormone response: For example, a pathogenic variant in the AR gene (Androgen Insensitivity Syndrome) means the body’s receptors may not respond fully to androgens [5]. A pathogenic variant in SRD5A2 means the body struggles to convert testosterone into DHT, but might still respond to DHT therapies. Knowing the underlying cause helps specialists predict if treatments like DHT gel might be considered, though responses are highly individualized [6][13].
- Predicting puberty: Genetic information can help predict potential physical changes during puberty. For example, some individuals with 5α-reductase deficiency may experience virilization (development of male physical traits) at puberty if their gonads are present [14][15].
Predicting Long-Term Health and Cancer Risks
Genetic testing can provide important context for long-term health, though it is one piece of a larger puzzle.
- Cancer risk and gonad management: A gonad is a reproductive gland (like a testis or ovary). In some DSDs, gonads may not develop fully (sometimes called streak gonads). The risk of developing tumors in these gonads varies. For example, certain variants in genes like NR5A1 or DHH are associated with a higher risk of gonadal tumors [16][17][18]. However, tumor risk is not determined by the gene alone; it depends heavily on the gonad’s location, structure, and the patient’s age. Decisions about whether to remove the gonads (gonadectomy) or monitor them through specialized surveillance are deeply personal. Surveillance has limits, and early removal is not automatically required for everyone. These decisions should always involve shared decision-making with a specialized multidisciplinary team [19][20].
- Whole-body health: Some DSD-related genetic variants can affect other organs. For instance, specific variants in the SAMD9 gene can be linked to adrenal insufficiency, while certain GATA4 variants may be associated with heart defects [21][22]. While not everyone with a DSD will have these issues, a genetic diagnosis helps doctors know if targeted screening of other organs is necessary.
Understanding Your Results
Genetic counseling is essential before and after testing. Your results may come back as:
- Pathogenic/Likely Pathogenic: A clear genetic cause was found.
- Negative: No genetic cause was found. This does not mean you don’t have a DSD; genetic testing has limits and cannot find every cause [2].
- Variant of Uncertain Significance (VUS): A DNA change was found, but there isn’t enough medical evidence yet to know if it causes the condition [23]. A VUS should not be used to make irreversible medical decisions.
Ultimately, genetic testing doesn’t replace traditional testing—it completes it. The most accurate diagnoses come from combining your clinical history, physical exam, imaging, hormone blood tests, and genetic sequencing [24].
Common questions in this guide
Why might hormone blood tests not identify the exact type of 46,XY DSD?
What kinds of genetic tests are used for 46,XY DSD?
What does a negative genetic test mean if I have 46,XY DSD?
How should I interpret a variant of uncertain significance?
Can a genetic result change how my gonads are monitored?
Could 46,XY DSD genetic testing identify health risks outside the reproductive system?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific DSD genes are included in the genetic testing panel you are recommending?
- 2.If the genetic test shows a 'Variant of Uncertain Significance' (VUS), how will we handle my care?
- 3.How might my genetic results change the surveillance or management of my gonads and tumor risk?
- 4.Does this genetic test cover all potential causes, or could it miss certain structural DNA changes?
- 5.Will the genetic testing look for variants that might affect my heart, adrenal glands, or other organs?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (24)
- 1
The laboratory in the multidisciplinary diagnosis of differences or disorders of sex development (DSD): III) Biochemical and genetic markers in the 46,XYIV) Proposals for the differential diagnosis of DSD.
Granada ML, Audí L
Advances in laboratory medicine 2021; (2(4)):494-515 doi:10.1515/almed-2021-0043.
PMID: 37360892 - 2
Genomic technologies and the diagnosis of 46, XY differences of sex development.
Idris F, Sinclair AH, Ayers KL
Andrology 2025; (13(5)):1025-1043 doi:10.1111/andr.13708.
PMID: 39081229 - 3
Spectrum of Pathogenic Variants in SRD5A2 in Indian Children with 46,XY Disorders of Sex Development and Clinically Suspected Steroid 5α-Reductase 2 Deficiency.
Kumar A, Sharma R, Faruq M, et al.
Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 2019; (13(5-6)):228-239 doi:10.1159/000509812.
PMID: 32894851 - 4
Clinical, hormonal and genetic characteristics of androgen insensitivity syndrome in 39 Chinese patients.
Liu Q, Yin X, Li P
Reproductive biology and endocrinology : RB&E 2020; (18(1)):34 doi:10.1186/s12958-020-00593-0.
PMID: 32345305 - 5
Clinical, Hormonal, Genetic, and Molecular Characteristics in Androgen Insensitivity Syndrome in an Asian Indian Cohort from a Single Centre in Western India.
Arya S, Barnabas R, Lila AR, et al.
Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 2021; (15(4)):253-261 doi:10.1159/000517763.
PMID: 34333495 - 6
The Molecular Basis of 5α-Reductase Type 2 Deficiency.
Batista RL, Mendonca BB
Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 2022; (16(2-3)):171-183 doi:10.1159/000525119.
PMID: 35793650 - 7
Hormonal evaluation in relation to phenotype and genotype in 286 patients with a disorder of sex development from Indonesia.
Juniarto AZ, van der Zwan YG, Santosa A, et al.
Clinical endocrinology 2016; (85(2)):247-57 doi:10.1111/cen.13051.
PMID: 26935236 - 8
Screening for mutations in 17β-hydroxysteroid dehydrogenase and androgen receptor in women presenting with partially virilised 46,XY disorders of sex development.
Phelan N, Williams EL, Cardamone S, et al.
European journal of endocrinology 2015; (172(6)):745-51 doi:10.1530/EJE-14-0994.
PMID: 25740850 - 9
Diagnostic Accuracy of Serum Steroids and Peptides in the Evaluation of 46, XY Disorders of Sex Development (DSD).
Barnabas R, Lila AR, Memon SS, et al.
Clinical endocrinology 2025; (103(6)):823-832 doi:10.1111/cen.70017.
PMID: 40799104 - 10
Diagnostic approach in 46, XY DSD: an endocrine society of bengal (ESB) consensus statement.
Baidya A, Basu AK, Bhattacharjee R, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(1)):4-18 doi:10.1515/jpem-2022-0515.
PMID: 36424806 - 11
Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort.
Eggers S, Sadedin S, van den Bergen JA, et al.
Genome biology 2016; (17(1)):243 doi:10.1186/s13059-016-1105-y.
PMID: 27899157 - 12
The genetic spectrum of a Chinese series of patients with 46, XY disorders of the sex development.
Zhang W, Mao J, Wang X, et al.
Andrology 2024; (12(1)):98-108 doi:10.1111/andr.13446.
PMID: 37147882 - 13
Correlation of androgen receptor and SRD5A2 gene mutations with pediatric hypospadias in 46, XY DSD children.
Fu XH, Zhang WQ, Qu XS
Genetics and molecular research : GMR 2016; (15(1)):15018232 doi:10.4238/gmr.15018232.
PMID: 27051040 - 14
Steroid 5α-reductase 2 deficiency.
Mendonca BB, Batista RL, Domenice S, et al.
The Journal of steroid biochemistry and molecular biology 2016; (163()):206-11.
PMID: 27224879 - 15
Gonadal function and pathology in 17beta-HSD 3 and 5alpha-reductase deficiency.
Boogers LS, Brüggenwirth HT, Wolffenbuttel KP, et al.
European journal of endocrinology 2025; (192(1)):34-45 doi:10.1093/ejendo/lvae154.
PMID: 39782875 - 16
A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development.
Pyle LC, Nathanson KL
American journal of medical genetics. Part C, Seminars in medical genetics 2017; (175(2)):304-314 doi:10.1002/ajmg.c.31562.
PMID: 28544305 - 17
Clinical Spectrum, Surgical Management, and Outcomes of NR5A1-Related 46,XY Differences of Sex Development: A Narrative Review.
Vicario S, Escolino M, Esposito G, et al.
Medicina (Kaunas, Lithuania) 2025; (61(11)) doi:10.3390/medicina61111965.
PMID: 41303802 - 18
46,XY Gonadal Dysgenesis due to a Homozygous Mutation in Desert Hedgehog (DHH) Identified by Exome Sequencing.
Werner R, Merz H, Birnbaum W, et al.
The Journal of clinical endocrinology and metabolism 2015; (100(7)):E1022-9 doi:10.1210/jc.2015-1314.
PMID: 25927242 - 19
A Risk of Gonadoblastoma in Familial Swyer Syndrome-A Case Report and Literature Review.
Rudnicka E, Jaroń A, Kruszewska J, et al.
Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030785.
PMID: 38337479 - 20
Two Korean girls with complete androgen insensitivity syndrome diagnosed in infancy.
Heo YJ, Ko JM, Lee YA, et al.
Annals of pediatric endocrinology & metabolism 2018; (23(4)):220-225 doi:10.6065/apem.2018.23.4.220.
PMID: 30599484 - 21
MIRAGE syndrome is a rare cause of 46,XY DSD born SGA without adrenal insufficiency.
Shima H, Hayashi M, Tachibana T, et al.
PloS one 2018; (13(11)):e0206184 doi:10.1371/journal.pone.0206184.
PMID: 30403727 - 22
GATA4 gene variants in 46,XY differences of sex development: report of four cases and literature review.
Mansó Borràs M, Pellicer Viudes C, De Mingo Alemany C, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2026; (39(5)):482-489 doi:10.1515/jpem-2025-0612.
PMID: 41832665 - 23
Integrating clinical and genetic approaches in the diagnosis of 46,XY disorders of sex development.
Kolesinska Z, Acierno J, Ahmed SF, et al.
Endocrine connections 2018; (7(12)):1480-1490.
PMID: 30496128 - 24
Contribution of Clinical and Genetic Approaches for Diagnosing 209 Index Cases With 46,XY Differences of Sex Development.
Gomes NL, Batista RL, Nishi MY, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(5)):e1797-e1806 doi:10.1210/clinem/dgac064.
PMID: 35134971
This page is for informational purposes only and does not constitute medical advice. A specialized multidisciplinary DSD team and genetic counselor should interpret your results and discuss hormone therapy, gonad monitoring, and other decisions for your situation.
Get notified when new evidence is published on 46,XY difference of sex development.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.